When switching, always initiate at the lowest dose unless instructed otherwise by your healthcare provider
In summary, rational design has led to the development of two long-acting GLP-1 analogs, liraglutide and semaglutide, that have made a vast contribution to the management of T2D in terms of improvements in glycemic control, body weight, blood pressure, lipids, beta-cell function, and CV outcomes
Weight loss occurs due to lessening of appetite and slowing of stomach emptying
The principle is the same for both: start low, increase slowly, let your body adapt
This approach takes longer but carries less risk of amplifying GI side effects during the overlap period when residual tirzepatide is still active
Your price stays flat at every standard dose